Clinical Trial Update: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema [Phase 3]

View source ↗

Summary

Open-label, long-term safety study of Avoralstat in hereditary angioedema (Phase 3) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Avoralstat (avoralstat)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema, HAE | Phase 3 | Status: TERMINATED